In honor Frederick G. Banting’s birth 125 years ago, we present a review of developments in insulin for the year 2016.
ADA 2017: Insulins go Head-to-Head
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
5 New & Upcoming Technologies: Diabetes Patients
Five new and upcoming medical devices will help your patients manage their diabetes care.
Interesting Endo: Fracture Risk & Endocrine Disruptors
Our April list includes predictors of fracture risk, endocrine-disrupting chemicals, and CV effects of thyroid dysfunction.
CV Events: Safety of Insulin
A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.
Endo 2017: Improve Diabetes, Obesity Care
Three studies from ENDO 2017 focused on improving patient care through brain stimulation, an artificial pancreas system, and videoconferencing.
Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
Type 1 Diabetes: First-Ever Exercise Guidelines
A new set of guidelines will help people with type 1 diabetes mellitus exercise safely to avoid fluctuations in blood sugar.
Combo Therapy vs Insulin: Type 2 Diabetes
The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.
Safety of Closed-Loop Insulin Delivery System
Dr. Bobby Lazzara reviews the safety of a hybrid closed-loop insulin delivery system for patients with type 1 diabetes in a real-world setting.
By clicking Accept, you agree to become a member of the UBM Medica Community.